You are here

News

October 13, 2016
MHRP and Collaborators at HIV Research for Prevention (HIVR4P) 2016

MHRP researchers and collaborators are scheduled to speak and present at the 2016 HIVR4P conference taking place October 17-21 in Chicago.

 

 

September 30, 2016
Experts Identify Challenges to Fast-Track Development of Zika Vaccine

Zika vaccine development is advancing rapidly thanks to cross-sector research and development collaboration along with promising preclinical findings that demonstrate an effective vaccine is feasible.

However, to maintain this momentum and ultimately develop, license, and deploy a vaccine capable of impacting the current epidemic, collaborators will need to anticipate and address...

August 22, 2016
HIV Infant Tracking System (HITSystem) Improves Early Diagnosis Outcomes in Tanzania

There have been significant advances in the management of HIV/AIDS over the years. However, the management of HIV-exposed infants (HEI) has been hampered by challenges of tracking the testing process and communication of results to the mothers for initiation of care in a timely manner. Early infant diagnosis (​​EID) of HIV infection is essential in ensuring timely initiation of antiretroviral...

August 3, 2016
Vaccine Candidates Protect Against Zika Virus in Rhesus Monkeys

The Walter Reed Army Institute of Research (WRAIR), in collaboration with the Beth Israel Deaconess Medical Center (BIDMC), has completed a second round of preclinical studies on a promising Zika vaccine candidate and found it to completely protect rhesus monkeys from experimental infection with Zika virus.

WRAIR researchers and partners recently reported the protective efficacy of a...

August 1, 2016
Early Antiretroviral Therapy Dramatically Reduces HIV DNA Set Point

A team of researchers, led by Drs. Merlin Robb and Jintanat Ananworanich of the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research, has found that when antiretroviral therapy (ART) is initiated during early acute HIV infection, it can significantly reduce total HIV DNA levels in the body, which may have implications for the goal of achieving long-term HIV...

July 13, 2016
MHRP Scientists and Collaborators Presenting at AIDS 2016

The AIDS 2016 conference will be held in Durban, South Africa, July 18-22. Read on to learn more about MHRP oral and poster presentations and well as special sessions that include MHRP speakers.

Saturday, July 16 —Towards and HIV Cure: Engaging the Community workshop, 9:00 a.m. Dr. Jintanat Ananworanich will participate in a panel discussion at this workshop on the research priorities...

July 13, 2016
U.S. Army Part of Team to Win HIV Cure Research Grant

MHRP is part of a collaborative research team, or “Collaboratory,” that was awarded funds to develop an integrated approach to finding an HIV cure. This research project brings together some of the leading researchers in the cure field and will help further our understanding of the role of immunity in HIV persistence.

The National Institutes of Health (NIH) funded this program as part...

July 6, 2016
WRAIR Teams with Sanofi Pasteur to Co-Develop Zika Virus Vaccine

The Walter Reed Army Institute of Research (WRAIR) announces a Cooperative Research and Development Agreement for the development of a Zika vaccine candidate with Sanofi Pasteur, the vaccines division of Sanofi. 

WRAIR scientists and collaborators are moving rapidly to develop and test the Zika Purified Inactivated Virus (ZPIV) vaccine candidate because it builds on “a flavivirus...

June 28, 2016
A Vaccine to Prevent Zika Infection in Humans is Feasible

The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable. Findings from the study were published today in the journal Nature.

In the preclinical study, WRAIR and the...

June 24, 2016
Initiation of ART during Acute HIV Infection Leads to High Rate of Non-Reactive HIV Serology

The initiation of antiretroviral therapy (ART) during acute HIV infection (AHI) may impact the development of antibodies to HIV, affecting the ability of diagnostic tests to detect HIV infection, according to a study published this month in Clinical Infectious Disease.

Scientists tested the sensitivity of several diagnostic technologies using samples drawn from participants in MHRP and...

Pages